We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · November 10, 2020

Manageable Cutaneous Toxicities in Melanoma Patients Receiving Checkpoint Inhibitor Therapy

Clinical and Experimental Dermatology


Additional Info

Clinical and Experimental Dermatology
Cutaneous Toxicities in Melanoma Patients Receiving Checkpoint Inhibitor Therapy, a Retrospective Review: The Experience of a Single Large Specialist Institution
Clin Exp Dermatol 2020 Oct 03;[EPub Ahead of Print], C Edwards, F Comito, S Agraso Busto, C Harland, S Turajlic, J Larkin, K Heelan, L Fearfield

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading